Dr. Byrd on Impact of Ibrutinib on Patients With CLL
John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).
John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).
Ohio State University have had to add a survivorship clinic to their institution due to the number of patients who have participated in ibrutinib clinical trials, including RESONATE. Moreover, Byrd explains, many of these patients would likely not have survived if they did not receive treatment with ibrutinib.
Hearing patients' stories and seeing them continue to live life magnifies the effect of ibrutinib on patients with CLL, he adds.
